| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSTM2L |
| Uniprot No | Q96N03 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-204aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMTRPAGHAPWDNHVSGHALFTETPHD MTARTGEDVEMACSFRGSGSPSYSLEIQWWYVRSHRDWTDKQAWASNQLK ASQQEDAGKEATKISVVKVVGSNISHKLRLSRVKPTDEGSYECRVIDFSD GKARHHKVKAYLRVQPGENSVLHLPEAPPAAPAPPPPKPGKELRKRSVDQ EACSL |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSTM2L重组蛋白的示例参考文献(注：部分文献为模拟示例，实际研究中可能需进一步验证)：
---
1. **文献名称**：*"Cloning, expression, and functional analysis of recombinant VSTM2L in immune regulation"*
**作者**：Zhang Y, et al.
**摘要**：本研究成功克隆了人源VSTM2L基因，并通过哺乳动物表达系统制备了重组蛋白。实验表明，重组VSTM2L蛋白可能通过调控T细胞表面受体信号通路参与免疫应答，为自身免疫疾病治疗提供潜在靶点。
2. **文献名称**：*"Recombinant VSTM2L suppresses tumor angiogenesis via blocking VEGF signaling"*
**作者**：Wang L, et al.
**摘要**：研究利用大肠杆菌表达系统纯化VSTM2L重组蛋白，发现其通过竞争性结合VEGF受体抑制血管生成，显著减少小鼠模型中肿瘤的生长和转移，提示其作为抗肿瘤药物的潜力。
3. **文献名称**：*"Structural characterization of VSTM2L and its role in adipocyte differentiation"*
**作者**：Chen X, et al.
**摘要**：通过X射线晶体学解析了重组VSTM2L蛋白的三维结构，并发现其通过激活BMP/Smad通路促进前脂肪细胞分化，为代谢性疾病研究提供了新方向。
4. **文献名称**：*"VSTM2L recombinant protein as a novel biomarker in inflammatory bowel disease"*
**作者**：Kim S, et al.
**摘要**：研究开发了高纯度VSTM2L重组蛋白，证实其在炎症性肠病患者血清中表达异常，可能通过调节肠道免疫稳态参与疾病进展，具有诊断和治疗应用价值。
---
**注意**：以上文献为模拟示例，实际研究中请通过PubMed、Web of Science或Google Scholar等数据库检索最新成果。若需具体文献，建议结合关键词“VSTM2L recombinant protein”或“VSTM2L function”进一步查询。
**Background of VSTM2L Recombinant Protein**
VSTM2L (V-set and transmembrane domain-containing protein 2-like) is a member of the immunoglobulin (Ig) superfamily, characterized by its extracellular V-set Ig-like domain and a transmembrane region. It is implicated in immune regulation, particularly in modulating T-cell activity, though its precise biological mechanisms remain under investigation. The protein is thought to interact with undiscovered ligands or receptors to influence signaling pathways involved in immune homeostasis, inflammation, or cell differentiation.
Recombinant VSTM2L is produced via genetic engineering, often using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functional fidelity. The purified protein typically includes tags (e.g., Fc or His tags) for detection, solubility, or affinity purification. Its structure preserves critical domains, such as the Ig-like fold, to maintain potential ligand-binding capabilities.
Research on VSTM2L has gained traction due to its possible roles in immune-related disorders and cancer. For example, studies suggest it may act as a checkpoint regulator or contribute to tumor microenvironment interactions, making it a candidate for immunotherapy development. Additionally, its expression patterns in certain tissues hint at tissue-specific functions.
Despite progress, VSTM2L's full interactome and signaling cascades remain unclear. Current efforts focus on elucidating its binding partners, downstream pathways, and therapeutic potential. Recombinant VSTM2L serves as a vital tool for structural studies, antibody development, and functional assays, bridging gaps in understanding its role in immunity and disease. Further research may position it as a biomarker or therapeutic target in precision medicine.
×
